Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845 for multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
IPO Year: 2021
Exchange: NASDAQ
Website: lyell.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/27/2024 | $6.00 → $1.00 | Buy → Neutral | H.C. Wainwright |
8/28/2023 | $15.00 → $5.00 | Overweight → Neutral | JP Morgan |
11/14/2022 | $15.00 → $7.00 | Overweight → Equal-Weight | Morgan Stanley |
11/11/2022 | $13.00 → $7.00 | Buy → Neutral | Goldman |
10/17/2022 | $12.00 | Buy | H.C. Wainwright |
1/6/2022 | $25.00 → $20.00 | Overweight | Morgan Stanley |
7/12/2021 | $25.00 | Buy | BofA Securities |
7/12/2021 | $25.00 | Overweight | Morgan Stanley |
7/12/2021 | $22.00 | Overweight | JP Morgan |
7/12/2021 | $30.00 | Buy | Goldman Sachs |
Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date (150 x 106 CAR T cells)First demonstration that CAR T cells enhanced with anti-exhaustion technology can both expand and infiltrate into solid tumorsNo significant safety signal related to LYL797 observed in patients without lung involvement; treatable pneumonitis observed in patients with lung metastatic disease; dose escalation continues in separate cohortsExpanding development into new tumor types including ROR1+ relapsed/refractory platinum-resistant ovarian cancer, endometrial cancer, multiple
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
Cash, cash equivalents and marketable securities of $632.7 million as of June 30, 2023 support advancing multiple product candidates through key clinical milestonesRemain on track for initial clinical data from two lead product candidates in 2024Further strengthened executive leadership with appointment of Matt Lang, J.D., as Chief Business Officer SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today reported financial results and business highlights for the second quarter ended June 30, 2023. "Lyell continues
SOUTH SAN FRANCISCO, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that Matthew Lang, J.D. has joined the executive management team as Chief Business Officer. In this newly created role, Mr. Lang will serve on Lyell's executive committee and will be responsible for Lyell's legal, compliance, human resources, alliance management and early commercialization teams. He will also serve as Lyell's Chief Legal Officer and Corporate Secretary. "Matt is an experienced company builder who has successfully led growth in compl
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced that Lynn Seely, MD, a member of the company's board and former president and chief executive officer (CEO) of Myovant Sciences, has been named Lyell's president & CEO effective today. Dr. Seely succeeds Ms. Liz Homans following a four-year tenure as president and then CEO. Ms. Homans will remain a consultant to the company through June 2024. Dr. Seely has extensive biopharmaceutical leadership experience with a track record of success building companies
Investigational New Drug (IND) application clearance of LYL845 advances second wholly owned product candidate into clinical developmentCash, cash equivalents and marketable securities of $750.7 million as of September 30, 2022; extends funding into 2026 and supports advancement of multiple product candidates through key clinical milestones SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell) (NASDAQ:LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, today provided business highlights and reported financial results for the third quarter of 2022. "In the past year we
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced that Rahsaan W. Thompson has joined the executive management team as chief legal officer. A biopharmaceutical industry veteran, Mr. Thompson has more than 20 years of experience with development stage and commercial companies. "Rahsaan's experience and expertise across corporate law and intellectual property make him an ideal fit for Lyell as we advance clinical development of multiple products in our pipeline targeting solid tumor cancers," said Liz Ho
Cash, cash equivalents and marketable securities of $838 million as of March 31, 2022 supports advancing a robust cell therapy pipelineResearch highlighting novel reprogramming technologies designed to overcome barriers to successful adoptive cell therapy in solid tumors presented at multiple scientific conferences SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Lyell) (NASDAQ:LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today provided business highlights and reported financial results for the first quarter of 2022. "We continue to progress our mission to develop T-cell therapies tha
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (NASDAQ:LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced the appointment of Gary Lee, Ph.D., as Chief Scientific Officer. A veteran biotech leader with more than a decade of experience heading translational cell and gene therapy programs, Dr. Lee will set and oversee the company's research strategy and advance its research pipeline. "We are thrilled to welcome Gary and his scientific expertise in translational cell therapy to the Lyell team," said Liz Homans, Chief Executive Officer of Lyell. "Beyond his exceptional scientifi
10-Q - Lyell Immunopharma, Inc. (0001806952) (Filer)
8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)
8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)
8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)
424B5 - Lyell Immunopharma, Inc. (0001806952) (Filer)
10-Q - Lyell Immunopharma, Inc. (0001806952) (Filer)
8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)
EFFECT - Lyell Immunopharma, Inc. (0001806952) (Filer)
ARS - Lyell Immunopharma, Inc. (0001806952) (Filer)
DEFA14A - Lyell Immunopharma, Inc. (0001806952) (Filer)
SC 13G/A - Lyell Immunopharma, Inc. (0001806952) (Subject)
SC 13G/A - Lyell Immunopharma, Inc. (0001806952) (Subject)
SC 13G - Lyell Immunopharma, Inc. (0001806952) (Subject)
SC 13G/A - Lyell Immunopharma, Inc. (0001806952) (Subject)
SC 13G - Lyell Immunopharma, Inc. (0001806952) (Subject)
SC 13G - Lyell Immunopharma, Inc. (0001806952) (Subject)
SC 13G - Lyell Immunopharma, Inc. (0001806952) (Subject)
SC 13G - Lyell Immunopharma, Inc. (0001806952) (Subject)
SC 13G - Lyell Immunopharma, Inc. (0001806952) (Subject)
SC 13G - Lyell Immunopharma, Inc. (0001806952) (Subject)
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors or hematologic malignancies, announced today that members of its senior management team will present and participate in the following upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4th at 10:45 am Eastern TimeH.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9th at 8:30 am Eastern Time A live webcast of the presentation can be accessed through the Investors section of th
Reported dose-dependent antitumor clinical activity in patients with relapsed/refractory triple-negative breast cancer from the Phase 1 trial of LYL797, a ROR1-targeted Chimeric Antigen Receptor (CAR) T‑cell product candidate enhanced with proprietary anti-exhaustion technology; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared at the time of the initial data report (150 x 106 CAR T cells)Expanded development of LYL797 into four new tumor types, including ROR1+ relapsed/refractory platinum‑resistant ovarian cancer, endometrial cancer, multiple myeloma and chronic lymphocytic leukemiaReceived FDA clearance of an IND for LYL119, a next-generation ROR1-target
Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date (150 x 106 CAR T cells)First demonstration that CAR T cells enhanced with anti-exhaustion technology can both expand and infiltrate into solid tumorsNo significant safety signal related to LYL797 observed in patients without lung involvement; treatable pneumonitis observed in patients with lung metastatic disease; dose escalation continues in separate cohortsExpanding development into new tumor types including ROR1+ relapsed/refractory platinum-resistant ovarian cancer, endometrial cancer, multiple
SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10 at 4:00 pm ET. A live webcast of the presentation can be accessed through the Investors section of the Company's website at www.lyell.com. Following the live presentation, a replay of the webcast will be available on the Company's website following the presentation date. About Lyell Immunopharma, Inc. Lyell i
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the BofA Securities 2024 Health Care Conference on Tuesday, May 14 at 8:40 am PT. A live webcast of the presentation can be accessed through the Investors section of the Company's website at www.lyell.com. Following the live presentation, a replay of the webcast will be available on the Company's website following the presentation date. About Lyell Immunopharma, Inc. Lyell is a clinical
Expect to share initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T‑cell product candidate, this quarterOn track to report initial clinical data from the Phase 1 trial of LYL845, an epigenetically enhanced TIL product candidate, in the second half of 2024IND for second generation ROR1-targeted CAR T-cell product candidate on track for submission this quarterCash, cash equivalents and marketable securities of $526.3 million as of March 31, 2024 supports advancing diverse pipeline through multiple clinical milestones into 2027 SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical‑stage T-c
PRESS RELEASE CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB) LONDON – 19 March 2024 -- CHARM Therapeutics ("CHARM", "The Company"), a 3D deep-learning research company discovering and developing transformational medicines, today announces the foundation of its Scientific Advisory Board (SAB) to provide expert insight and guidance to the Company on the optimal application of 3D deep learning, protein design and prediction in real world medicine. The newly formed Board is comprised of world-leading experts whose skillsets span 3D deep learning and protein structure prediction, drug discovery and oncology. These individuals have a deep understanding of CHARM and
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced that three abstracts of new nonclinical data have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024 taking place in San Diego, CA, April 5-10. One oral and two poster presentations will highlight data from Lyell's product pipeline and research programs, including: An oral presentation on Lyell's rejuvenation technology which has shown the potential to turn back the epigenetic clock to generate more
On track to report initial clinical and translational data from lead CAR T-cell and TIL product candidates in 2024Received Orphan Drug Designation for LYL845 for the treatment of melanomaExpect to submit IND for second generation ROR1-targeted CAR T-cell product in the first half of 2024Presented nonclinical data demonstrating the ability of Lyell's novel genetic and epigenetic reprogramming technologies to generate potent T-cell product candidates with durable cytotoxic function at multiple scientific conferencesAdvanced manufacturing innovations to reduce cost and build scale for both CAR T-cell and TIL product candidatesCash, cash equivalents and marketable securities of $562.7 million as
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced today that members of its senior management team will present and participate the following upcoming investor conferences: TD Cowen's 44th Annual Health Care Conference on Monday, March 4th at 11:10 am Eastern TimeH.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on March 26th at 3:30 pm Eastern Time A live webcast of the presentation can be accessed through the Investors section of the Company's website at www.lyell.com. Following the live pres
B of A Securities analyst Geoff Meacham maintains Lyell Immunopharma (NASDAQ:LYEL) with a Buy and lowers the price target from $9 to $6.
HC Wainwright & Co. analyst Mitchell Kapoor downgrades Lyell Immunopharma (NASDAQ:LYEL) from Buy to Neutral and lowers the price target from $6 to $1.
Lyell Immunopharma Inc (NASDAQ:LYEL) shares are trading lower on Wednesday on a heavy session volume of 5.79 million shares as per data from Benzinga Pro. The company released initial clinical and translational data from its Phase 1 trial of LYL797, its first-generation reprogrammed ROR1 CAR T‑cell product candidate enhanced with proprietary anti-exhaustion technology. This initial dataset of 20 treated patients includes 16 patients with TNBC and four patients with non-small cell lung cancer and demonstrated dose-dependent antitumor clinical activity and the ability of LYL797 CAR T cells to proliferate, infiltrate tumors, and kill cancer cells in patients with relapsed/refractory disea
Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date (150 x 106 CAR T cells) First demonstration that CAR T cells enhanced with anti-exhaustion technology can both expand and infiltrate into solid tumors No significant safety signal related to LYL797 observed in patients without lung involvement; treatable pneumonitis observed in patients with lung metastatic disease; dose escalation continues in separate cohorts Expanding development into new tumor types including ROR1+ relapsed/refractory platinum-resistant ovarian cancer, endometrial cancer,
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Buy and maintains $6 price target.
Lyell Immunopharma (NASDAQ:LYEL) reported $3.000 thousand in sales this quarter. This is a 95.38 percent decrease over sales of $65.000 thousand the same period last year.
U.S. stock futures were mixed this morning, with the Dow futures gaining around 100 points on Tuesday. Shares of Live Nation Entertainment, Inc. (NYSE:LYV) fell sharply in today’s pre-market trading following a report indicating the Justice Department will file an antitrust lawsuit against the company. Live Nation Entertainment shares dipped 7.8% to $92.02 in pre-market trading. Here are some big stocks recording losses in today’s pre-market trading session. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) shares dipped 24.3% to $8.32 in pre-market trading. INOVIO priced its $36 million underwritten offering of 2,536,258 common stock at $7.693 per share. Groupon, Inc. (NASDAQ:GRPN) shares d
Shares of JPMorgan Chase & Co. (NYSE:JPM) fell sharply during Friday’s session following first-quarter earnings. Net revenue (managed) of $42.5 billion (+8% Y/Y), beating the consensus of $41.8 billion. Excluding an item resulted in an increase of $550 million (after tax) to reported net income from $13.4 billion to $14.0 billion and an increase of $0.19 per share to reported EPS from $4.44 to $4.63. EPS was $4.44, beating the consensus of $4.15. JPMorgan Chase shares dipped 5.1% to $185.49 on Friday. Here are some other stocks moving in today's mid-day session. Gainers PaxMedica, Inc. (NASDAQ:PXMD) jumped 143% to $1.0101 after the company announced the completed execution of its thr
H.C. Wainwright downgraded Lyell Immunopharma from Buy to Neutral and set a new price target of $1.00 from $6.00 previously
JP Morgan downgraded Lyell Immunopharma from Overweight to Neutral and set a new price target of $5.00 from $15.00 previously
Morgan Stanley downgraded Lyell Immunopharma from Overweight to Equal-Weight and set a new price target of $7.00 from $15.00 previously
Goldman downgraded Lyell Immunopharma from Buy to Neutral and set a new price target of $7.00 from $13.00 previously
H.C. Wainwright initiated coverage of Lyell Immunopharma with a rating of Buy and set a new price target of $12.00
Morgan Stanley reiterated coverage of Lyell Immunopharma with a rating of Overweight and set a new price target of $20.00 from $25.00 previously
BofA Securities initiated coverage of Lyell Immunopharma with a rating of Buy and set a new price target of $25.00
Morgan Stanley initiated coverage of Lyell Immunopharma with a rating of Overweight and set a new price target of $25.00
JP Morgan initiated coverage of Lyell Immunopharma with a rating of Overweight and set a new price target of $22.00
Goldman Sachs initiated coverage of Lyell Immunopharma with a rating of Buy and set a new price target of $30.00